Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes

Pharmacogenetics and Genomics

Volumn 27, Issue 4, 2017, Pages 135-142

  Zimdahl, Heike ^a   Haupt, Axel ^e   Brendel, Michael ^a   Bour, Louis ^a   Machicao, Fausto ^b,c   Salsali, Afshin ^a   Broedl, Uli C ^a   Woerle, Hans Juergen ^a   Häring, Hans Ulrich ^b,c,d   Staiger, Harald ^b,c,d  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

genetic polymorphism; genetic predisposition; sodium glucose cotransporter 2; type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; GENETIC VARIATION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PHARMACOGENETIC TESTING; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; AGED; ANALYSIS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85010966919     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000268     Document Type: Article

References (26)

1. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-794.
2. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495-502.
3. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-141.
4. Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 2006; 69: 852-855.
5. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, et al. Twentyone additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 2008; 23: 3874-3879.
6. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14: 2873-2882.
7. Calado J, Santer R, Rueff J. Effect of kidney disease on glucose handling (including genetic defects). Kidney Int Suppl 2011; 120: S7-S13.
8. Enigk U, Breitfeld J, Schleinitz D, Dietrich K, Halbritter J, Fischer-Rosinsky A, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics 2011; 12: 1119-1126.
9. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O, et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005; 48: 2282-2291.
10. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-1659.
11. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404.
12. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-219.
13. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-158.
14. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-Terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467.
15. Zimdahl H, Ittrich C, Graefe-Mody U, Boehm BO, Mark M, Woerle HJ, et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 2014; 57: 1869-1875.
16. Wagner R, Heni M, Linder K, Ketterer C, Peter A, Böhm A, et al. Agedependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol 2014; 51: 71-78.
17. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Staiger H, Bohm A, Scheler M, Berti L, Machann J, Schick F, et al. Common genetic variation in the human FNDC5 locus, encoding the novel musclederived browning' factor irisin, determines insulin sensitivity. PLoS One 2013 8 e61903.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
21. Myburgh R, Hochfeld WE, Dodgen TM, Ker J, Pepper MS. Cardiovascular pharmacogenetics. Pharmacol Ther 2012; 133: 280-290.
22. Becker ML, Pearson ER, Tkac I. Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol 2013; 2013: 686315.
23. Tonjes A, Kovacs P. SGLT2: a potential target for the pharmacogenetics of type 2 diabetes?. Pharmacogenomics 2013; 14: 825-833.
24. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013; 62: 3324-3328.
25. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 2014; 306: F188-F193.
26. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks? treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 613-621.